OneStream, Inc. Class A Common Stock OS
24.00 USD 0.00 (+0.00%)
Apr 1, 2026, 9:30 AM EDT
24.00 Day range 24.00
52-week range unavailable
- YTD
- +30.58%
- 1 year
- +5.82%
News
defenseworld.net Arteris (NASDAQ:AIP) and OneStream (NASDAQ:OS) Financial Comparison Arteris (NASDAQ: AIP - Get Free Report) and OneStream (NASDAQ: OS - Get Free Report) are both technology companies, but which is the better stock? We will contrast the two businesses based on the…
gurufocus.com Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 Positive results from the CLARITY-Gastric01 global Phase III trial showed AstraZeneca's sonesitatug vedotin (Sone-Ve) demonstrated a statistically significant a
gurufocus.com TAGRISSO® (osimertinib) plus savolitinib reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO Positive results from the SAFFRON Phase III trial showed TAGRISSOÂ (osimertinib) plus savolitinib demonstrated a statistically significant and clinically meani
gurufocus.com Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 S Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the n
gurufocus.com IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER IMDELLTRAÂ IN COMBINATION WITH IMFINZIÂ REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCERPR NewswireTHOUSAND
gurufocus.com IMFINZI® (durvalumab) plus tarlatamab-dlle reduced the risk of death by 58% in 1st-line extensive-stage small cell lung cancer in the DeLLphi-305 Phase III trial Landmark results from the DeLLphi-305 Phase III trial showed IMFINZIÂ (durvalumab) plus Amgen's tarlatamab-dlle demonstrated a statistically significant and hi
gurufocus.com Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer Positive results from the VOLGA Phase III trial showed perioperative treatment with AstraZeneca's IMFINZIÂ (durvalumab) in combination with neoadjuvant enfortu
gurufocus.com BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim an
gurufocus.com Ziihera® (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 Ziihera (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 202
gurufocus.com /C O R R E C T I O N - AbbVie/ /C O R R E C T I O N - AbbVie/PR NewswireNORTH CHICAGO, Ill., Oct. 18, 2026In the news release, AbbVie to Present Data at the 2026 European Society for Medical
gurufocus.com AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPR News
gurufocus.com New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists [url="]Natera, Inc.[/url] (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Soci
gurufocus.com Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 [url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of
defenseworld.net Head to Head Comparison: OneStream (NASDAQ:OS) and Minim (NASDAQ:FIEE) Minim (NASDAQ: FIEE - Get Free Report) and OneStream (NASDAQ: OS - Get Free Report) are both technology companies, but which is the better investment? We will contrast the two companies based on the…
defenseworld.net OneStream (NASDAQ:OS) and Dassault Systemes (OTCMKTS:DASTY) Head to Head Analysis Dassault Systemes (OTCMKTS:DASTY - Get Free Report) and OneStream (NASDAQ: OS - Get Free Report) are both technology companies, but which is the superior business? We will contrast the two companies…
gurufocus.com RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 RYBREVANT FASPRO⢠(amivantamab and hyaluronidase-lpuj) plus LAZCLUZE (lazertinib) with prophylactic strategies shows low rates of treatment-related events a
gurufocus.com TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca's TAGRISSOÂ (osimertinib) demonstrated a sustained, clinically meaningful overal
gurufocus.com Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer Johnson and Johnson's RYBREVANTÂ (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positi
gurufocus.com Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial e
gurufocus.com Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condu Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. [url="]announced[/url] that updated data, including overall survival (OS), from
benzinga.com Earnings Scheduled For February 26, 2026 
benzinga.com SanDisk To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday 
benzinga.com 12 Information Technology Stocks Moving In Tuesday's Intraday Session 
benzinga.com Microchip Technology, Alumis, Terrestrial Energy, Bright Minds Biosciences And Other Big Stocks Moving Higher On Tuesday 
benzinga.com 12 Information Technology Stocks Moving In Tuesday's Pre-Market Session 
benzinga.com Why Cyclerion Therapeutics Shares Are Trading Higher By 44%; Here Are 20 Stocks Moving Premarket 
benzinga.com Dropbox, Globus Medical, Expedia, Genpact And Other Big Stocks Moving Higher On Friday 
benzinga.com 12 Information Technology Stocks Moving In Friday's Intraday Session 
benzinga.com Earnings Scheduled For November 6, 2025 
benzinga.com Earnings Scheduled For August 7, 2025 
benzinga.com Waystar, OneStream, Vertex Among Analyst Favorites As Solid Guidance Fuel Bullish Outlook After a rough start to the year, small- and mid-cap software stocks may be finding their footing. Goldman Sachs analyst Adam Hotchkiss says first-quarter results across his coverage were better than…
benzinga.com Earnings Scheduled For May 8, 2025 
benzinga.com 12 Information Technology Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Teradata Posts Weak Revenue, Joins Lyft, Vertiv, Zillow And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session 
benzinga.com 12 Information Technology Stocks Moving In Wednesday's Pre-Market Session 
benzinga.com Why Upstart Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket 
benzinga.com Earnings Scheduled For February 11, 2025